Alpelisib (BYL-719) (Standard) is the analytical standard of Alpelisib ( HY-15244 ). This product is intended for research and analytical applications. Alpelisib (BYL-719) is an orally active PI3Kα -selective inhibitor that blocks the conversion of PIP2 to PIP3 , thereby inhibiting pathways including PI3K/AKT/mTOR , MAPK/ERK , Notch and JAK-STAT . Alpelisib also induces apoptosis , G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib not only enhances the sensitivity to Eribulin ( HY-13442 ) and exerts a synergistic effect with Paclitaxel ( HY-B0015 ), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib can be applied to research related to breast cancer , gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome.
Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Others | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Metabolic Disease | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > Reference Standards | Products > Signaling Pathways > PI3K | Products > Signaling Pathways > Apoptosis
感谢您来到爆牛贸易,请为我们留言或者使用以下方式联系我们,我们将尽快给您回复,并为您提供最真诚的服务,谢谢。